CA3119065A1 - Utilisation de vecteurs viraux adeno-associes pour corriger des defauts de gene/exprimer des proteines dans des cellules ciliees et de soutien dans l'oreille interne - Google Patents

Utilisation de vecteurs viraux adeno-associes pour corriger des defauts de gene/exprimer des proteines dans des cellules ciliees et de soutien dans l'oreille interne Download PDF

Info

Publication number
CA3119065A1
CA3119065A1 CA3119065A CA3119065A CA3119065A1 CA 3119065 A1 CA3119065 A1 CA 3119065A1 CA 3119065 A CA3119065 A CA 3119065A CA 3119065 A CA3119065 A CA 3119065A CA 3119065 A1 CA3119065 A1 CA 3119065A1
Authority
CA
Canada
Prior art keywords
amino acid
acid substitutions
amino acids
cell target
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3119065A
Other languages
English (en)
Inventor
Emmanuel J. Simons
Robert NG
Danielle LENZ
Michelle VALERO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akouos Inc
Original Assignee
Akouos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akouos Inc filed Critical Akouos Inc
Publication of CA3119065A1 publication Critical patent/CA3119065A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions comprenant au moins deux vecteurs d'acide nucléique différents qui, lorsqu'ils sont introduits dans une cellule de primate, subissent une concatémérisation ou une recombinaison homologue entre eux, ce qui permet de former un acide nucléique recombiné qui code une protéine cible pleine longueur (par exemple, une protéine cible de cellule de soutien ou une protéine cible de cellule ciliée). L'invention concerne en outre des compositions comprenant un seul vecteur AAV qui, lorsqu'il est introduit dans une cellule de primate, produit un acide nucléique codant pour une protéine cible pleine longueur (par exemple, une protéine cible de cellule de soutien ou une protéine cible de cellule ciliée) au niveau du locus du gène cible de cellule de soutien, et le primate exprime la protéine cible (par exemple, une protéine cible de cellule de soutien ou une protéine cible de cellule ciliée).
CA3119065A 2018-11-07 2019-11-07 Utilisation de vecteurs viraux adeno-associes pour corriger des defauts de gene/exprimer des proteines dans des cellules ciliees et de soutien dans l'oreille interne Pending CA3119065A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862756953P 2018-11-07 2018-11-07
US62/756,953 2018-11-07
US201962888093P 2019-08-16 2019-08-16
US62/888,093 2019-08-16
PCT/US2019/060328 WO2020097372A1 (fr) 2018-11-07 2019-11-07 Utilisation de vecteurs viraux adéno-associés pour corriger des défauts de gène/exprimer des protéines dans des cellules ciliées et de soutien dans l'oreille interne

Publications (1)

Publication Number Publication Date
CA3119065A1 true CA3119065A1 (fr) 2020-05-14

Family

ID=70611216

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3119065A Pending CA3119065A1 (fr) 2018-11-07 2019-11-07 Utilisation de vecteurs viraux adeno-associes pour corriger des defauts de gene/exprimer des proteines dans des cellules ciliees et de soutien dans l'oreille interne

Country Status (7)

Country Link
US (2) US20230056182A1 (fr)
EP (2) EP4063510A1 (fr)
JP (2) JP2022506613A (fr)
CN (2) CN113853437A (fr)
AU (1) AU2019377115A1 (fr)
CA (1) CA3119065A1 (fr)
WO (1) WO2020097372A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3510161A4 (fr) 2016-08-23 2020-04-22 Akouos, Inc. Compositions et méthodes pour traiter une déficience auditive non associée à l'âge chez un sujet humain
EP3727468A4 (fr) 2017-12-19 2021-09-22 Akouos, Inc. Administration d'anticorps thérapeutiques médiée par aav à l'oreille interne
WO2019200016A1 (fr) 2018-04-10 2019-10-17 President And Fellows Of Harvard College Vecteurs aav codant pour clarine-1 ou gjb2 et utilisations associées
CN112703016B (zh) 2018-04-27 2024-11-22 分贝治疗公司 肌球蛋白15启动子及其用途
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CA3129422A1 (fr) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Promoteurs de myosine 15 et utilisations associees
EP3921032A4 (fr) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. Compositions et procédés de traitement de la surdité neurosensorielle à l'aide de systèmes à deux vecteurs pour l'otoferline
EP3959324B1 (fr) 2019-04-26 2025-09-17 President and Fellows of Harvard College Vecteurs aav codant pour mini-pcdh15 et leurs utilisations
KR20220130093A (ko) 2019-10-30 2022-09-26 데시벨 테라퓨틱스, 인크. 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
WO2021231808A2 (fr) * 2020-05-13 2021-11-18 Akouos, Inc. Compositions et procédés de traitement de la perte auditive associée à gjb2
US20240016955A1 (en) * 2020-09-14 2024-01-18 President And Fellows Of Harvard College Dual-aav vector delivery of pcdh15 and uses thereof
TW202227476A (zh) * 2020-09-14 2022-07-16 哈佛大學校長及研究員協會 編碼GJB2之重組腺相關病毒(rAAV)及其用途
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
AU2021376225A1 (en) * 2020-11-06 2023-06-22 Eli Lilly And Company Variant adeno-associated virus (aav)capsid polypeptides and gene therapeutics thereof for treatment of hearing loss
IL303317A (en) * 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
IL304006A (en) 2020-12-29 2023-08-01 Akouos Inc Compositions and methods for treating hearing loss and/or vision loss associated with CLRN1
US20220267795A1 (en) * 2021-02-24 2022-08-25 Kinase Pharma Inc. Compositions and methods for regulating production of an angiogensis inhibitor
TW202342525A (zh) * 2022-02-02 2023-11-01 美商阿科奧斯公司 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法
CN120344669A (zh) * 2022-09-30 2025-07-18 分贝治疗公司 Slc26a4调控元件及其用途
WO2025179016A1 (fr) * 2024-02-20 2025-08-28 Skylark Bio, Inc. Virus adéno-associé recombiné et utilisations associées

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0928202A4 (fr) * 1996-09-25 2001-09-05 Cell Genesys Inc Administration non invasive de vecteur viraux aav
AU4185699A (en) * 1998-05-27 1999-12-13 Avigen, Inc. Adeno-associated viral vector-mediated expression of factor viii activity
WO2011075838A1 (fr) * 2009-12-21 2011-06-30 Audigen Inc. Procédé pour traitement ou prévention de perte d'audition
CA2890061A1 (fr) * 2012-12-04 2014-06-12 Merck Sharp & Dohme Corp. Vecteurs viraux a replication conditionnelle
AU2014255665B2 (en) * 2013-04-18 2018-08-02 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
TWI906646B (zh) * 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的ｃｒｉｓｐｒ酶突變
SG10201913266UA (en) * 2015-12-11 2020-02-27 Massachusetts Eye & Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
WO2017136764A1 (fr) * 2016-02-05 2017-08-10 The General Hospital Corporation Système hybride pour l'administration efficace d'un gène à des cellules de l'oreille interne
KR20240005973A (ko) * 2016-04-15 2024-01-12 리젠엑스바이오 인크. 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
EP3510161A4 (fr) * 2016-08-23 2020-04-22 Akouos, Inc. Compositions et méthodes pour traiter une déficience auditive non associée à l'âge chez un sujet humain
KR102746901B1 (ko) * 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법

Also Published As

Publication number Publication date
JP2024086735A (ja) 2024-06-28
WO2020097372A1 (fr) 2020-05-14
WO2020097372A8 (fr) 2021-04-29
EP4063510A1 (fr) 2022-09-28
CN113853437A (zh) 2021-12-28
US20250041457A1 (en) 2025-02-06
JP2022506613A (ja) 2022-01-17
US20230056182A1 (en) 2023-02-23
AU2019377115A1 (en) 2021-05-20
EP3880826A1 (fr) 2021-09-22
CN118497276A (zh) 2024-08-16
EP3880826A4 (fr) 2022-08-24

Similar Documents

Publication Publication Date Title
US20250041457A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
KR101708544B1 (ko) 세포 증식 질환을 분석하기 위한 방법 및 핵산
KR102149483B1 (ko) 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
CA2941594A1 (fr) Polymorphismes genetiques de recepteur de proteine c (procr) associes a un infarctus du myocarde, methodes de detection et utilisations associees
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
KR20220012230A (ko) 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
AU2016351889A1 (en) Detection of foetal chromosomal aneuploidies using DNA regions that are differentially methylated between the foetus and the pregnant female
KR20220024184A (ko) 대장암의 검출
KR20170086027A (ko) 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
KR20220025749A (ko) 대장암의 검출
KR20180049093A (ko) 신규한 바이오마커 및 암의 치료 방법
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
KR20210144822A (ko) Ube3a-ats를 조절하기 위한 화합물 및 방법
WO2006022629A1 (fr) Procédés d’identification de risque de diabète de type ii et leurs traitements
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
WO2006022636A1 (fr) Méthodes d’identification du risque d’apparition de diabètes de type ii et traitements associés
KR102001153B1 (ko) 유방암 예후 예측용 조성물 및 방법
KR102647919B1 (ko) App 돌연변이 세포 및 이의 이용
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
WO2018209358A2 (fr) Administration systémique de polypeptides
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
JP2003259875A (ja) ヒト遺伝子の一塩基多型（４）
KR20150094601A (ko) 성별에 독립적인 연령 결정 방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231228

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250602

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251002

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251203